1245.24.491002 Boehringer Ingelheim Investigational Site

Melsungen

0 studies enrolling now · 1 studies all time

What they study most

Diabetes Mellitus, Type 2

Studies at this site

• Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension — Completed